Dissemin is shutting down on January 1st, 2025

Published in

Wiley, Experimental Dermatology, 11(22), p. 767-769, 2013

DOI: 10.1111/exd.12254

Links

Tools

Export citation

Search in Google Scholar

Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The Bcl-2 family member Mcl-1 is essential for melanoma survival, however, the influence of oncogenic BRAF signalling remains elusive. In the present study Mcl-1 splice variant expression was determined in a panel of melanoma cell lines in relation to BRAF mutational status. Mcl-1L mRNA expression was increased in melanoma cells compared to primary melanocytes with significantly increased mRNA and protein expression observed in BRAF(V600E) mutant melanoma cells. Although no change in Mcl-1S mRNA was observed, Mcl-1S protein expression also increased in BRAF mutant melanoma cells. Additionally, while over-expression of mutant BRAF(V) (600E) increased both Mcl-1L and Mcl-1S expression, inhibition of hyperactive BRAF signalling resulted in decreased Mcl-1L expression. These studies suggest the regulation of Mcl-1 expression by BRAF signalling is increased by oncogenic activation of BRAF, revealing a mechanism of apoptotic resistance which may be overcome by the use of more specifically targeted Mcl-1 inhibitors. This article is protected by copyright. All rights reserved.